Table 5.

Time-dependent Cox regression analyses of outcome results in-trial and post-trial

Amlodipine versus ChlorthalidoneLisinopril versus Chlorthalidone
In-TrialPost-TrialTime InteractionIn-TrialPost-TrialTime Interaction
HR (95% CI)PHR (95% CI)PPHR (95% CI)PHR (95% CI)PP
eGFR <60
ESRD0.95 (0.70–1.29) 0.731.02 (0.74–1.40) 0.900.740.95 (0.70–1.29) 0.730.87 (0.63–1.21) 0.410.71
Nonfatal MI and fatal CHD0.96 (0.78–1.18) 0.720.76 (0.58–1.00) 0.050.180.94 (0.77–1.16) 0.581.01 (0.78–1.30) 0.940.68
Combined CVD1.10 (0.95–1.27) 0.190.92 (0.78–1.10) 0.360.121.07 (0.92–1.23) 0.380.94 (0.79–1.11) 0.450.25
Stroke1.12 (0.85–1.48) 0.421.03 (0.77–1.38) 0.820.691.03 (0.78–1.37) 0.821.10 (0.83–1.47) 0.510.75
Heart failure 1.23 (0.97–1.55) 0.091.00 (0.77–1.30) 0.990.261.24 (0.98–1.57) 0.080.88 (0.67–1.16) 0.360.07
All-cause mortality1.06 (0.94–1.21) 0.351.00 (0.88–1.13) 0.990.510.99 (0.87–1.13) 0.910.93 (0.82–1.05) 0.240.46
CVD mortality1.16 (0.97–1.38) 0.110.91 (0.76–1.10) 0.340.070.97 (0.80–1.17) 0.750.95 (0.79–1.14) 0.610.89
Non-CVD mortality0.91 (0.75–1.11) 0.351.07 (0.90–1.26) 0.450.231.00 (0.83–1.21) 0.970.92 (0.78–1.10) 0.380.53
  • HR, hazard ratio; 95% CI, 95% confidence interval; eGFR, estimated GFR; MI, myocardial infarction; CHD, coronary heart disease; CVD, cardiovascular disease.